Cubist Systematic Strategies LLC Acquires Shares of 49,775 PDS Biotechnology Co. (NASDAQ:PDSB)

Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology Co. (NASDAQ:PDSBFree Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 49,775 shares of the company’s stock, valued at approximately $146,000. Cubist Systematic Strategies LLC owned 0.14% of PDS Biotechnology at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Kathleen S. Wright Associates Inc. acquired a new position in shares of PDS Biotechnology in the 1st quarter valued at about $28,000. Tempus Wealth Planning LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth approximately $55,000. Ground Swell Capital LLC purchased a new position in shares of PDS Biotechnology during the 2nd quarter valued at approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at $115,000. Finally, Squarepoint Ops LLC purchased a new stake in PDS Biotechnology during the second quarter worth $120,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Price Performance

Shares of NASDAQ PDSB opened at $3.23 on Wednesday. The firm has a 50-day simple moving average of $3.25 and a 200-day simple moving average of $3.28. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $118.47 million, a price-to-earnings ratio of -2.38 and a beta of 1.90. PDS Biotechnology Co. has a 52 week low of $2.53 and a 52 week high of $6.85.

PDS Biotechnology (NASDAQ:PDSBGet Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter in the previous year, the business earned ($0.37) earnings per share. On average, equities analysts predict that PDS Biotechnology Co. will post -1.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

PDSB has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research report on Wednesday, October 2nd. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $14.25.

View Our Latest Stock Analysis on PDSB

PDS Biotechnology Company Profile

(Free Report)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.

Recommended Stories

Want to see what other hedge funds are holding PDSB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PDS Biotechnology Co. (NASDAQ:PDSBFree Report).

Institutional Ownership by Quarter for PDS Biotechnology (NASDAQ:PDSB)

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.